Ryan CJ - Search Results

1

A phase II study of insulin-like growth factor receptor inhibition with nordihydroguaiaretic acid in men with non-metastatic hormone-sensitive prostate cancer.

Friedlander TW, Weinberg VK, Huang Y, Mi JT, Formaker CG, Small EJ, Harzstark AL, Lin AM, Fong L, Ryan CJ. Friedlander TW, et al. Among authors: ryan cj. Oncol Rep. 2012 Jan;27(1):3-9. doi: 10.3892/or.2011.1487. Epub 2011 Oct 4. Oncol Rep. 2012. PMID: 21971890 Clinical Trial.

2

Role of secondary hormonal therapy in the management of recurrent prostate cancer.

Ryan CJ, Small EJ. Ryan CJ, et al. Urology. 2003 Dec 29;62 Suppl 1:87-94. doi: 10.1016/j.urology.2003.10.002. Urology. 2003. PMID: 14747046

3

Advances in prostate cancer.

Ryan CJ, Small EJ. Ryan CJ, et al. Curr Opin Oncol. 2004 May;16(3):242-6. doi: 10.1097/00001622-200405000-00009. Curr Opin Oncol. 2004. PMID: 15069320 Review.

4

Progress in detection and treatment of prostate cancer.

Ryan CJ, Small EJ. Ryan CJ, et al. Curr Opin Oncol. 2005 May;17(3):257-60. doi: 10.1097/01.cco.0000155008.37524.8e. Curr Opin Oncol. 2005. PMID: 15818171 Review.

5

Secondary hormonal manipulations in prostate cancer.

Ryan CJ, Small EJ. Ryan CJ, et al. Curr Oncol Rep. 2005 May;7(3):228-33. doi: 10.1007/s11912-005-0078-x. Curr Oncol Rep. 2005. PMID: 15847715 Review.

6

Early versus delayed androgen deprivation for prostate cancer: new fuel for an old debate.

Ryan CJ, Small EJ. Ryan CJ, et al. J Clin Oncol. 2005 Nov 10;23(32):8225-31. doi: 10.1200/JCO.2005.03.5311. J Clin Oncol. 2005. PMID: 16278477 Review.

7

Chemotherapy for hormone-refractory prostate cancer: now it's a question of "when?".

Ryan CJ, Eisenberger M. Ryan CJ, et al. J Clin Oncol. 2005 Nov 10;23(32):8242-6. doi: 10.1200/JCO.2005.03.3092. J Clin Oncol. 2005. PMID: 16278479 Review.

8

Prostate cancer update: 2005.

Ryan CJ, Small EJ. Ryan CJ, et al. Curr Opin Oncol. 2006 May;18(3):284-8. doi: 10.1097/01.cco.0000219259.83585.f3. Curr Opin Oncol. 2006. PMID: 16552242 Review.

9

Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationale.

Ryan CJ, Lin AM, Small EJ. Ryan CJ, et al. Urol Oncol. 2006 May-Jun;24(3):250-3. doi: 10.1016/j.urolonc.2005.11.021. Urol Oncol. 2006. PMID: 16678059 Review.

10

A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy.

Lin AM, Rini BI, Weinberg V, Fong K, Ryan CJ, Rosenberg JE, Fong L, Small EJ. Lin AM, et al. Among authors: ryan cj. BJU Int. 2006 Oct;98(4):763-9. doi: 10.1111/j.1464-410X.2006.06396.x. BJU Int. 2006. PMID: 16796694 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

477 results

Search Page

Filters